SCHEMBL2566955

SCHEMBL2566955

COCCSc1nc2c(c(=O)n1-c1ccc(OCC(F)(F)F)cc1)CC(=O)N2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.45
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 2/20 0.37
TP53 P04637 4/20 0.36
GAA P10253 3/20 0.35
LMNA P02545 2/20 0.34
APLNR P35414 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
KCNH2 Q12809 3/20 0.33
HRH3 Q9Y5N1 3/20 0.33
RXFP1 Q9HBX9 1/20 0.33
THRB P10828 1/20 0.33
POLB P06746 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2561526 0.92 FADS1 (0.42) FADS1MAPTALDH1A1KDM4EHPGD
SCHEMBL2563697 0.91 TSHR (0.46) FADS1MAPTALDH1A1TSHRTP53
SCHEMBL2997555 0.89 FADS1 (0.46) FADS1MAPTALDH1A1TSHRTP53
SCHEMBL2564174 0.89 FADS1 (0.42) FADS1TSHRGAAKMT2AMEN1
SCHEMBL2565032 0.89 TSHR (0.45) FADS1MAPTALDH1A1KDM4ETSHR
SCHEMBL2566866 0.88 FADS1 (0.44) FADS1MAPTTSHRTP53GAA
SCHEMBL2566412 0.88 FADS1 (0.43) FADS1MAPTALDH1A1TSHRTP53
SCHEMBL2566730 0.88 FADS1 (0.42) FADS1ALDH1A1TSHRTP53GAA
SCHEMBL2568118 0.87 FADS1 (0.43) FADS1TSHRGAAKMT2A
SCHEMBL2561188 0.87 FADS1 (0.42) FADS1MAPTALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES FADS1 140/4885MAPT 2366/4885ALDH1A1 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.